Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission

Bone Marrow Transplantation

Volumn 41, Issue 1, 2008, Pages 33-38

  Martino, R ^a   Valcarcel D ^a   Brunet, S ^a   Sureda, A ^a   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CD34 SELECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONOZYGOTIC TWINS; MYELOABLATIVE CONDITIONING; MYELODYSPLASIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA WITH EXCESS BLASTS; RISK ASSESSMENT; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 38349195008     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705879     Document Type: Article

References (25)

1. Appelbaum FR, Pearce SF. Hematopoietic Cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 2006; 19: 333-339.
2. de WT, Oosterveld M, Span B, Muus P, Schattenberg A. Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy. Rev Clin Exp Hematol 2002; 6 72-85.
3. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836-846.
4. de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 2006; 43: 107-117.
5. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
6. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006; 19: 825-838.
7. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: Is this strategy correct. Leukemia 2006; 20: 1673-1682.
8. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
9. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006, 20: 128-135.
10. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
11. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic-haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
12. Martino R, Caballero MD, Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
13. Martino R, Perez-Simon JA, Moreno E, Queralto JM, Caballero D, Mateos M et al. Reduced-intensity Conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. Biol Blood Marrow Transplant 2005; 11: 437-447.
14. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
15. Brunet S, Esteve J, Berlanga, J, Ribera JM, Bueno, J, Marti JM et al Treatment of primary acute myeloid leukemia: Results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Haematologica 2004; 89: 940-949.
16. Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A et al Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003; 88: 637-645.
17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
18. Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant 2001; 28: 349-354.
19. Newell DJ. Intention-to-treat analysis: Implications for quantitative and qualitative research. Int J Epidemiol 1992; 21: 837-841.
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
21. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991; 7 (suppl 3): 9-12.
22. Valcarcel D, Martino R, Caballero D, Mateos MV, Perez-Simon JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
23. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF. Assessment of differences in-patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933-3939.
24. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R et al Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400.
25. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 2006; 91: 1513-1522.